We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Glu5.5
Glucosamine Research
Likely helps
252 peer-reviewed studies
What the evidence says
Probably helps
Glucosamine helped in about half (9/13) of the studies that measured an effect — promising, but not unanimous.
Most evidence is from high-quality meta-analyses and randomised trials published 1975–2026 with a typical study size of 205 participants.
Based on 252 studies · 44 meta-analyses · 187 RCTs · 521,688 total participants
Confidence
High confidence
What the studies found
9helped1unclear3didn't help· 239 more without graded effect data
By outcome
Joint pain & arthritisReduced joint pain and improved mobility within 4-8 weeks · 4-8 weeks
Probably helps170 studies
Glucose & metabolic
Mostly mechanism / observational13 studies
Safety profile
Mostly mechanism / observational4 studies
InflammationMay reduce joint pain and slow cartilage loss · 4-12 weeks
Mostly mechanism / observational3 studies
Therapeutic & clinical
Mostly mechanism / observational3 studies
Heart & blood pressure
Too few graded studies1 study
By the numbers
Pulled from 29 studies with measurable effects
Likely real effects
67%
across studies
People studied
522k
typical study: 205 people
Strongest designs
231
44 pooled, 187 randomised
Showed benefit
69%
9/13 studies
How long studies ran
1–3 months
2
3+ months
8
Populations Studied
Patients with knee osteoarthritis5
Patients with osteoarthritis3
General population2
Knee osteoarthritis patients2
Steady research
36 studies in the last 5 years · Latest meta-analysis: 2025
197520002026
1Safety of anti-osteoarthritis medicationsSystematic ReviewCited 6×n=22,938 · very large study2025
This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs.
Honvo G et al. · Drugs (2025)
This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs.
Beyond the evidence here reported, the limitations of this research highlight the urgent need of a reporting guideline for post-marketing safety surveillance studies.
Importantly, real-life safety surveillance of anti-OA medications should be strengthened with large cohort studies with control groups, and results should be disaggregated by disease populations for drugs common to several conditions.
Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.
Meng Z et al. · Archives of orthopaedic and trauma surgery (2023)
Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.
It is worthwhile to popularize and apply the combination in KOA treatment considering the point of effect, tolerability and economic costs.
Additionally, regarding the limited number of studies and uneven trial quality, more high-quality trials are required to investigate the accurate clinical advantages of the combination.
3Knee osteoarthritis treatment effectivenessMeta-AnalysisCited 8×n=1,930 · large study2022
JWGT is considered effective and safe in the treatment of KOA and is worthy of clinical application.
Zhao J et al. · Journal of ethnopharmacology (2022)
Huge harm
← WorseNo effectBetter →
Likely real
The effective rate (OR = 2.56, 95% CI = 1.83 to 3.57, P < 0.001) and incidence of adverse reactions was significantly lower in the JWGT group than in the control group (OR = 0.13, 95% CI = 0.07 to 0.21, P < 0.001).
Compared with hyaluronic acid (HA) alone, JWGT + HA had better clinical efficacy (OR = 3.08, 95% CI = 1.48 to 6.40, P < 0.001).
JWGT is considered effective and safe in the treatment of KOA and is worthy of clinical application.
4PainMeta-AnalysisCited 20×n=2,952 · very large study2015
Well-planned, well-conducted and well-published trials are warranted to improve the evidence for Ayurvedic interventions.
Kessler CS et al. · Rheumatology international (2015)
Huge benefit
← WorseNo effectBetter →
Likely real
For the compound preparation, Rumalaya, large and apparently unbiased effects beyond placebo were found for pain (standardized mean difference [SMD] -3.73; 95 % confidence interval [CI] -4.97, -2.50; P < 0.01) and global improvement (risk ratio 12.20; 95 % CI 5.83, 25.54; P < 0.01).
There is also some evidence that effects of the herbal compound preparation Shunti-Guduchi are comparable to those of glucosamine for pain (SMD 0.08; 95 % CI -0.20, 0.36; P = 0.56) and function (SMD 0.15; 95 % CI -0.12, 0.36; P = 0.41).
No severe adverse events were observed in all trials.
5Efficacy for osteoarthritis and joint painSystematic ReviewCited 1×n=146 · medium study2025
Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.
Baden KER et al. · Nutrients (2025)
Huge benefit
← WorseNo effectBetter →
Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S.
Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects.
Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.
6Meta-AnalysisCited 38×n=16,427 · very large study2015
The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
Zeng C et al. · Scientific reports (2015)
All treatment options showed clinically significant improvement from baseline pain, but only glucosamine plus chondroitin showed clinically significant improvement from baseline function.
In terms of the structure-modifying effect, both glucosamine alone and chondroitin alone achieved a statistically significant reduction in joint space narrowing.
The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
A review of randomized trials of mostly low quality reveals that chondroitin (alone or in combination with glucosamine) was better than placebo in improving pain in participants with osteoarthritis in short-term studies.
Singh JA et al. · The Cochrane database of systematic reviews (2015)
Loss of minimum joint space width in the chondroitin group was statistically significantly less than in the placebo group, with a relative risk difference of 4.7% less (95% CI 1.6% to 7.8% less; n = 2 trials) (level of evidence, high; risk of bias, low).
Chondroitin was associated with statistically significantly lower odds of serious adverse events compared with placebo with Peto odds ratio of 0.40 (95% CI 0.19 to 0.82; n = 6 trials) (level of evidence, moderate).
Chondroitin did not result in statistically significant numbers of adverse events or withdrawals due to adverse events compared with placebo or another drug.
8Knee and hip osteoarthritis treatmentMeta-AnalysisCited 66×n=1,663 · large study2017
Although proposed and debated for several years, open trial data are not widely made available for studies of glucosamine for OA, especially those sponsored by industry.
Runhaar J et al. · Annals of the rheumatic diseases (2017)
Five trials (all independent of industry, n=1625) compared glucosamine with placebo, representing 55% of the total number of participants in all published placebo-controlled RCTs.
Although proposed and debated for several years, open trial data are not widely made available for studies of glucosamine for OA, especially those sponsored by industry.